psychedelicalpha.comPsychedelic Alpha - Commentary, Consultancy,

Community Access exclusive insights, data and interviews with Pα+ : learn more and subscribe today . Insights All Insights 2023 Year in Review Pα+ Dashboard Data Psychedelic Company Financing Tracker Psychedelic Drug Development Tracker Worldwide Psychedelic Laws U.S. Psychedelic Policy Reform Psychedelic Patent Trackers Psychedelic Stocks & Companies Advisory Careers Feed Contact Pα+ Menu Insights All Insights 2023 Year in Review Pα+ Dashboard Data Psychedelic Company Financing Tracker Psychedelic Drug Development Tracker Worldwide Psychedelic Laws U.S. Psychedelic Policy Reform Psychedelic Patent Trackers Psychedelic Stocks & Companies Advisory Careers Feed Contact Pα+ Subscribe Search Search Close this search box. Welcome to Psychedelic Alpha. Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture. Plus incubation, consultancy, and advisory for this emerging field. ∎ Insights, Delivered Join over ten thousand psychedelic insiders… Email Join For in-depth analysis and insights, consider our paid offering… Subcribe to Pα+ Our data and insights are cited in… Data Open access data on psychedelic policy reform, patents and drug development activity. Explore Support Consultancy, advisory and incubation offerings for investors, entrepreneurs, and beyond. Learn more Our data and insights are cited in… Our latest insights We’re Going to See Demand for This Go Through the Roof”: VA Under Secretary for Health Shares How the Agency Is Preparing for MDMA, Psilocybin Therapies May 15, 2024 Last Friday, the Under Secretary for Health at the Department of Veterans Affairs (VA), Shereef Elnahal, spoke on stage at Horizons’ 16th conference in New York City alongside Healing Breakthrough’s Executive Director Jason Pyle. Industry and Researchers Respond to ICER Report on MDMA-Assisted Therapy, Which Maintains Lykos’ Clinical Evidence Is Insufficient” May 14, 2024 Here, we review some of the public comments submitted in response to the draft evidence report, ICER’s responses to those comments, as well as notable changes between the draft and revised report. Breaking: AbbVie Inks Deal with Gilgamesh Pharmaceuticals May 13, 2024 One of the world’s largest pharmaceutical companies has entered into a collaboration and option-to-license agreement with the privately-held psychedelic drug developer Gilgamesh Pharmaceuticals. If Gilgamesh’s candidates see success, it could reap up to $1.95 billion in aggregate option fees and milestones. More Insights Subscribe to Pα+ Pα+ subscribers receive regular Bulletins, articles, interviews with insiders and quick-take analysis of major stories and developments (e.g., significant trial results, financing rounds, policy reforms, etc.); along with access to our back catalogue and Library. Learn More & Subscribe We Support INCUBATION & GROWTH Entrepreneurs and Startups Whether you’re at the idea-formation stage or raising early-stage funding, we’re here to help across the entire psychedelic value chain and company life-cycle. Explore how we can help ADVISORY & CONSULTANCY Investors and Corporates We help investors and corporates of all stripes understand and support the psychedelics space: from syndicates and VCs through to institutions. Work with us INSIGHTS & ANALYSIS Psychedelic Insiders and the Curious Join our newsletter to stay abreast of the rapidly emergent psychedelics industry: from clinical trials and patents through to healing centres and decriminalisation. Subscribe The Psychedelic Renaissance After a half-century of prohibition, psychedelics are once again entering the mainstream. Today’s so-called psychedelic renaissance” is represented by a seemingly exponential increase in research and development activity, billions of dollars of funding, psychedelic policy reform initiatives and successes across the world, and changing public perceptions. ∎ R&D Clinical Trials Clinical trials involving psychedelics started, per year Phase 3 trials of MDMA-assisted therapy have been completed, with Phase 3 study of psilocybin underway. Investment $4+ billion Invested in public and private psychedelic companies since 2020. Policy Reform Psychedelic policy reforms are gaining pace at the federal, state and local level in the U.S. and internationally. Perceptions 80.9% of psychiatrists agreed that psychedelics show promise in treating psychiatric disorders. Barnett et al., 2023 On Alpha” ‘Alpha’, in the investing world, refers to an excess return on investment relative to a benchmark. But we broaden the definition of alpha on both ends to include more than just economic returns on more than just economic investments. Instead, we conceptualise alpha as the excess return on myriad investments that people may make in the present and future of psychedelics: beyond economic capital, people might invest time, energy, and effort, for example. And that excess return might not be (purely) financial, it might also be realised through a more impactful treatment paradigm for mental health, for example, where the ‘benchmark’ is the inadequate status quo. All this to say, we’re not only for investors. In fact, most of our readers aren’t: many of them are practitioners, regulators, entrepreneurs, and so on. ∎ Psychedelic Alpha Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond Quick Links Insights Jobs Data Subscribe to Pα+ Contact Newsletter Insights and interviews delivered to your inbox. No spam, just valuable information. Email Join Subscribe to Pα+ Psychedelic Alpha © 2024, All Rights Reserved Privacy Policy Terms of Service Subscribe to Our Free Newsletter Email Sign-up Join Pα+ for Premium Insights Learn More &...